Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Kendrith M, Rowland"'
Autor:
Debra L. Barton, Stephanie L. Pugh, Patricia A. Ganz, Steven C. Plaxe, Bridget F. Koontz, Jeanne Carter, Natalya Greyz-Yusupov, Seth J. Page, Kendrith M. Rowland, Ernie P. Balcueva, Sobia Nabeel, Jack B. Basil, Matthew L. Hill, Carolyn Y. Muller, Maria C. Bell, Snehal Deshmukh, Lisa A. Kachnic
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 4
PURPOSE Because of the negative impact of cancer treatment on female sexual function, effective treatments are warranted. The purpose of this multisite study was to evaluate the ability of two dose levels of extended-release bupropion, a dopaminergic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869482ad9f3e8cd06513bb0f950998b3
https://doi.org/10.1200/jco.21.01473
https://doi.org/10.1200/jco.21.01473
Autor:
Jaime N. Wong, Edward McAuley, Arthur F. Kramer, Dominick A. Strom, Linda Trinh, Kendrith M. Rowland
Publikováno v:
Journal of Behavioral Medicine. 44:172-186
The purpose of this study was to evaluate the feasibility of delivering a supervised physical activity program plus standard exercise counseling (PA + EC) versus a supervised physical activity plus motivationally-enhanced behavioral counseling (PA +
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8347a5e06e205db014373b359bd2a3dc
https://doi.org/10.1007/s10865-020-00185-8
https://doi.org/10.1007/s10865-020-00185-8
Autor:
Kendrith M. Rowland, Gary R. Hudes, Timothy M. Kuzel, Mark N. Stein, Yu-Hui Chen, Robert S. DiPaola, Robert Dalune, Pauline M. Lerma, Michael A. Carducci, Winston Tan
Publikováno v:
Am J Clin Oncol
BACKGROUND: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. METHODS: In a multicenter ECOG trial, patients with progressive metastatic CRPC, EC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a596a4ba00ce406b1f7e0bec0c9f3c
https://doi.org/10.1097/coc.0000000000000526
https://doi.org/10.1097/coc.0000000000000526
Autor:
Ashlesha Patel, Ju-Whei Lee, Howard A. Zaren, Erika K Radeke, Rachel E. Lerner, Jami Aya Fukui, Della F. Makower, Deimante Tamkus, Kendrith M. Rowland, William M. Adler, Alyssa Throckmorton, Sharad A. Ghamande, Mary Helen Hackney, Andrew William Pippas, Rubina Qamar, David Cella, Michael Jordan Fisch, Lynne I. Wagner
Publikováno v:
Journal of Clinical Oncology. 40:1519-1519
1519 Background: Reproductive health (RH) needs of women newly diagnosed with cancer have been poorly addressed. RH management must be aligned with cancer treatment to optimize cancer survivorship. The primary objective of the EROS trial is to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b147adf9d80df3f3e2c8fd03be00dfbf
https://doi.org/10.1200/jco.2022.40.16_suppl.1519
https://doi.org/10.1200/jco.2022.40.16_suppl.1519
Publikováno v:
BMJ Case Rep
A 73-year-old woman was brought to the oestrogen receptor for altered mental status. She was found to be hypotensive and hypoglycaemic and admitted to the intensive care unit. She had a history of chronic watery diarrhoea which had recently increased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26fad732de82cfa4a3324697061ac211
https://pubmed.ncbi.nlm.nih.gov/33257365
https://pubmed.ncbi.nlm.nih.gov/33257365
Autor:
Betsy LaPlant, Dennis F. Moore, Nassim H. Nabbout, Axel Grothey, Kendrith M. Rowland, Thomas E. Witzig, Daniel A. Nikcevich, Patrick B. Johnston, Levi Pederson, Paul J. Kurtin
Publikováno v:
American Journal of Hematology. 92:1004-1010
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a520aa6af237e198c6b7c713ef151f
https://doi.org/10.1002/ajh.24824
https://doi.org/10.1002/ajh.24824
Autor:
Eric G. Wolfe, Charles L. Loprinzi, Daniel Flora, Mark L Graham, Roberto A. Leon-Ferre, Stephanie S. Faubion, Kathryn J. Ruddy, Christopher S R Dakhil, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, Paul J. Novotny, Thomas J. Smith
Publikováno v:
JNCI Cancer Spectrum
Background Hot flashes (HFs) negatively affect quality of life among perimenopausal and postmenopausal women. This study investigated the efficacy of oxybutynin vs placebo in decreasing HFs. Methods In this randomized, multicenter, double-blind study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58afbbf681dc920bde148a3ab777a896
https://pubmed.ncbi.nlm.nih.gov/32337497
https://pubmed.ncbi.nlm.nih.gov/32337497
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Background Many breast cancer survivors (BCS) report deficits in cognitive function. Physical activity (PA) has been associated with better processing speed and memory in healthy adults and thus may be a useful method for improving cognition in BCS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c108b2992251ba1d0a153a99ff296f
https://doi.org/10.1186/s12885-019-5589-1
https://doi.org/10.1186/s12885-019-5589-1
Autor:
Jeannine M. Brant, Scott D. Ramsey, Sherry Shen, Barbara Segarra-Vazquez, Kendrith M. Rowland, Riha Vaidya, Justin D. Floyd, Mina S. Sedrak, Amy K. Darke, Cynthia Law, Mark Allen O'Rourke, Dawn L. Hershman, Joseph M. Unger, Anna C. Beck
Publikováno v:
Journal of Clinical Oncology. 38:TPS12126-TPS12126
TPS12126 Background: The undertreatment of pain in patients with advanced or metastatic cancer is well described in cancer research. Overcoming barriers that prevent successful use of opioid analgesics for cancer pain requires a clear understanding o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf7c8c77fb9943dcb445376681f7fe53
https://doi.org/10.1200/jco.2020.38.15_suppl.tps12126
https://doi.org/10.1200/jco.2020.38.15_suppl.tps12126
Autor:
Erik Asmus, Claudine Isaacs, Donald B. Wender, Lauren J. Rogak, Ethan Basch, Bret Edward Buckley Friday, DeQuincy Andrew Lewis, Thomas H. Openshaw, Gini F. Fleming, Alvaro Moreno-Aspitia, Amylou C. Dueck, Minetta C. Liu, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, Alan P. Lyss, Ashley Frith, John T. Cole, Anthony J. Jaslowski, Douglas Weckstein, David W. Hillman
Publikováno v:
Journal of Clinical Oncology. 38:1016-1016
1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e71bf43f76db7bbccf5c0151772ab159
https://doi.org/10.1200/jco.2020.38.15_suppl.1016
https://doi.org/10.1200/jco.2020.38.15_suppl.1016